| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT04682431 Details | 2024-03-22 Interventional | 1 | 127 | Pembrolizumab Adenocarcinoma Adenocarcinoma … Advanced Solid … Breast Cancer Colorectal Canc… Gastric Adenoca… Gynecologic Can… Head and Neck C… Lung Adenocarci… Pancreatic Canc… | Sponsor business decision. - | |||
| NCT04521621 2020-001908-42 Details | 2024-03-22 Interventional | 1/2 | 75 | Pembrolizumab Neoplasm Metast… | Business Reasons - | |||
| NCT04113616 Details | 2024-03-22 Interventional | 1/2 | 70 | Cytarabine Decitabine Leukemia Leukemia, Myelo… Leukemia, Myelo… Myeloproliferat… Acute Myeloid L… Relapsed or Ref… | In September 2023, the study was terminated because of a Sponsor decision, unrelated to safety
concerns. - | |||
| NCT04075136 Details | 2024-03-22 Interventional | 4 | 0 | Ranibizumab Triamcinolone Triamcinolone A… Triamcinolone d… Triamcinolone h… Verteporfin Macular Degener… Wet Macular Deg… Exudative Age R… | IRB stopped study due to safety concerns before any participants were enrolled. - | |||
| NCT03644706 Details | 2024-03-22 Interventional | 3 | 3 | Potassium Citra… Acidosis Acidosis, Renal… Distal Renal Tu… | Research operation issues - | |||
| NCT03417999 Details | 2024-03-22 Interventional | 1 | 28 | Dexmedetomidine Heart Defects, … Heart Diseases Congenital Hear… Dexmedetomidine | All subjects who were enrolled completed the study. However, the PI left the institution and
the study was terminated before all cohorts were enrolled. Unable to enroll subjects in Cohort 1B to determine if DEX PK is different in patients spontaneously ventilating with a natural airway versus mechanically ventilated via oral endotracheal tube. Unable to sample long enough to determine elimination phase of IN DEX. Small sample size and heterogenous population limit interpretation of results. COVID delayed enrollment and loss of research personnel. PI left institution prior to completion of study and so study was terminated. | |||
| NCT05836571 Details | 2024-03-21 Interventional | 2 | - | Ipilimumab Nivolumab Chondrosarcoma Histiocytoma, M… Leiomyosarcoma Liposarcoma Sarcoma Locally Advance… Locally Advance… Locally Advance… Locally Advance… Locally Advance… Metastatic Undi… | Other - Administrative and regulatory issues. - | |||
| NCT05344365 Details | 2024-03-21 Interventional | 2 | 0 | Iloperidone Mental Disorder… Parkinson Disea… Psychotic Disor… Parkinson Disea… | Study was terminated for business reasons; not due to safety or efficacy concerns. - | |||
| NCT05172570 Details | 2024-03-21 Interventional | 3 | 20 | Gabapentin Pain, Postopera… Thoracotomy | Study terminated to to shortage if study supplies for epidurals and most enrolled has study
deviations due to not receiving correct post study drug assignments. - | |||
| NCT04586335 Details | 2024-03-21 Interventional | 1 | 24 | Olaparib Endometrial Neo… Breast Cancer Endometrial Can… Ovarian Cancer Prostate Cancer Solid Tumor | Business decision - | |||
| NCT04243941 Details | 2024-03-21 Interventional | 2 | 0 | Gallium 68 PSMA… Prostatic Neopl… Prostate Cancer | Funding unavailable - | |||
| NCT05967286 Details | 2024-03-20 Interventional | 2 | 0 | Olaparib Phosphoinositid… Poly(ADP-ribose… Breast Neoplasm… Carcinoma Anatomic Stage … Anatomic Stage … Metastatic HER2… Unresectable HE… | Other - Protocol moved to Withdrawn - | |||
| NCT05711628 Details | 2024-03-20 Interventional | 3 | 0 | Antibodies Antibodies, Mon… Antineoplastic … Bendamustine Hy… Brentuximab Ved… Carboplatin Doxorubicin Etoposide Etoposide phosp… Gemcitabine Ifosfamide Immunoconjugate… Immunoglobulins Isophosphamide … Liposomal doxor… Pembrolizumab Podophyllotoxin Vinorelbine Hodgkin Disease Lymphoma Recurrent Class… Refractory Clas… | Other - Protocol moved to Withdrawn - | |||
| NCT05498792 Details | 2024-03-20 Interventional | 1 | - | Ipilimumab Nivolumab Melanoma Locally Advance… | Paused for safety cohort review - | |||
| NCT04142658 Details | 2024-03-20 Interventional | 3 | 863 | Apixaban Warfarin Aortic Valve Di… Aortic Valve St… Aortic Valve Fa… | Safety - | |||
| NCT03602066 Details | 2024-03-20 Interventional | 2 | 14 | Chlorine dioxid… Mucositis Head and Neck C… | Study terminated by pharmaceutical company This study stopped accrual early as the IP manufacturer terminated the study stopping funding and IP. 14 out of 20 subjects were accrued, 11 of which completed study. Due to early termination with few patients, only the counts of events have been calculated and no testing was done. | |||
| NCT02460302 Details | 2024-03-20 Interventional | 2 | 0 | Progesterone Atrophic Vagini… Atrophy Vaginitis Menopause Vulvovaginal At… | Inadequate staffing and funds - | |||
| NCT05382338 Details | 2024-03-19 Interventional | 3 | - | Antidotes Cisplatin Cyclophosphamid… Lomustine Mesna Sodium thiosulf… Vincristine Medulloblastoma | Drug Supply Issues - | |||
| NCT04793399 Details | 2024-03-19 Interventional | 1/2 | 9 | Atezolizumab Bosutinib Leukemia Leukemia, Myelo… Leukemia, Myelo… Leukemia, Myelo… Chronic Phase-C… | The study has been prematurely terminated due to the onset of 2 dose limiting toxicities in 2
patients. - | |||
| NCT04083898 Details | 2024-03-19 Interventional | 1 | 15 | Bendamustine Hy… Prednisone Multiple Myelom… Neoplasms, Plas… | Decision made to not move forward with Phase II portion of trial - |